Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy
In routine practice, a short course of preoperative ET yields substantial reductions in tumor proliferation. Early assessment of Ki67 suppression offers a readily accessible indicator of endocrine sensitivity, and achieving CCCA identifies patients who have a more favorable prognosis and thus are potentially eligible to de-escalate in treatment strategies.
Authors
- Francesco Schettini (ORCID: https://orcid.org/0000-0001-6561-1919)
- B. Adamo
- O. Castillo
- A. Rodríguez (ORCID: https://orcid.org/0000-0002-4899-6607)
- F. Brasó-Maristany
- R Gómez-Bravo (ORCID: https://orcid.org/0009-0000-4090-4395)
- P. Blasco (ORCID: https://orcid.org/0000-0002-8858-210X)
- María del Carmen Quintela González
- M. Vidal
- N. Chic
- Pol Giménez‐Xavier (ORCID: https://orcid.org/0000-0003-1611-5083)
- Blanca González‐Farré (ORCID: https://orcid.org/0000-0002-1796-7248)
- Tomás Pascual (ORCID: https://orcid.org/0000-0001-8431-3183)
- Benjamín Walbaum (ORCID: https://orcid.org/0000-0003-2314-5360)
- Patricia Galván (ORCID: https://orcid.org/0000-0002-8153-0307)
- Isabel García-Fructuoso (ORCID: https://orcid.org/0000-0002-7417-4703)
- Esther Sanfeliu (ORCID: https://orcid.org/0000-0002-7974-3346)
- Montserrat Muñoz-Mateu (ORCID: https://orcid.org/0000-0001-7772-1437)
- Aleix Prat (ORCID: https://orcid.org/0000-0003-2377-540X)
- M. Rey
- M Bergamino
- E Seguí
- O. Martínez-Sáez
Institutions
- Breast Cancer Research Foundation (US)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105845
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Fundación BBVA
- Veracyte
- Seagen
- Fundación Científica Asociación Española Contra el Cáncer
- Eisai
- Banco Bilbao Vizcaya Argentaria
- Sociedad Española de Oncología Médica
- Instituto de Salud Carlos III
- Daiichi Sankyo Europe